



Contact: Pauline T. Mayer
PTM Healthcare Marketing, Inc.
631.979.3780 or PTM@ptmhcm.com

EKOS Corporation Receives \$2.7 Million N.I.H. Grant for Hemorrhagic Stroke Product Development to Address the Unmet Needs of 100,000 Americans with Intracerebral Hemorrhagic Stroke

BOTHELL, WASHINGTON – (Business Wire) –June 7, 2010: *EKOS Corporation announced today that they received a \$2.7 million grant from the National Institutes of Health (NIH) for the development of a product to provide therapy for intracerebral hemorrhagic stroke (ICH).*

ICH is a devastating form of stroke crippling more than 100,000 Americans each year with high mortality and costs. The financial burden of ICH is approximately \$125,000 per ICH patient per year resulting in an overall annual cost of \$6 billion for ICH patients in the United States.¹

ICH is fatal in approximately 50% of all occurrences and the majority of survivors have significant motor and cognitive disability. In 40% of ICH cases, ICH bleeding extends into the brain cavities (ventricles) causing Intraventricular Hemorrhage (IVH) increasing mortality to 80%. There are currently no good medical therapies for either ICH or IVH.

Data from a recent study known as Safety of lysis with EKOS ultrasound in the treatment of ICH and IVH (SLEUTH) headed by principal investigator, Dr. David Newell, co-executive director, Swedish Neuroscience Institute, (Seattle, WA) was presented at the 2010 American Heart Association's International Stroke Conference in San Antonio. Newell said, "EKOS innovative and minimally invasive technology combines local delivery of tissue Plasminogen Activator (rt-PA) with ultrasound

¹ Hsieh PC, Awad IA, Getch CC, Bendok BR, Rosenblatt SS, Batjer HH. Current updates in perioperative management of intracerebral hemorrhage. *Neurol Clin.* 2006;24:745-64.

enhancement that results in effective blood clot removal. There is no doubt the results of this study shows the potential for the EKOS ultrasound as a minimally invasive treatment option....”. View press conference with Dr. Newell [here](#). View patient’s accounting of his life-threatening experience [here](#). View ultrasound therapy animation [here](#).

EKOS President/CEO Robert W. Hubert said, “The NIH award allows EKOS to optimize our technology in a product specifically designed for this critically unmet area of medicine. The findings from the SLEUTH study clearly show the promise of increased survival and improved outcomes with EKOS technology”

About EKOS Corporation: EKOS Corporation pioneered the development and clinical application of ultrasonic accelerated drug delivery in medicine, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists, cardiothoracic and vascular surgeons at leading institutions around the world use the EKOS EkoSonic® Endovascular System to provide faster, safer and more complete dissolution of thrombus. The EkoSonic System is FDA-cleared for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. It is currently used to treat patients with peripheral arterial occlusions (PAO) and deep vein thrombosis (DVT). Therapy for ischemic stroke, hemorrhagic stroke and pulmonary embolism are being investigated. Visit www.ekoscorp.com.